AUS
NZ
UK
CA
USA
IND
Highlights
- Polynovo faces leadership change amid corporate governance issues.
- Botanix sees growth in US pharmaceutical sales, boosting its market position.
- EZZ secures a US partner for manufacturing dietary supplements, expanding its market reach.
Polynovo (ASX:PNV) is seeing a significant change in its leadership dynamics following revelations of corporate governance challenges. CEO Swami Raote will depart immediately, despite being under contract until June 2025. The decision comes after the board's decision, deeming new leadership vital for the company's growth trajectory. Reports have highlighted allegations involving improper behavior by the chairman, which led to an in-depth probe by legal experts to address these governance issues. Dr. Robyn Elliott will take on the role of acting CEO as the company navigates through these choppy waters. The market response has been negative, with the company's shares experiencing a marked decline.
Adherium's Legal Battle
In a turn of legal events, former Adherium (ASX:ADR) CEO Dr. Paul Mastoridis has initiated legal proceedings in New Jersey, alleging violations under the New Jersey Conscientious Employee Protection Act. Adherium, known for its devices that monitor asthma medication compliance, denies the accusations and is resolute in contesting them. Despite these challenges, Adherium has reported a revenue increase and remains optimistic about its growth goals, although market performance remains subdued.
Botanix's Expansion in the US Market
Botanix Pharmaceuticals (ASX:BOT) is making strides in the US with promising sales figures for its treatment for axillary hyperhidrosis. Approved by the US FDA, the company has executed a soft launch for its product, Sofdra, to an encouraging market reception. With a significant rise in patient prescriptions and refills, Botanix is on a robust growth trajectory. The company's market cap has substantially increased, earning it a spot in the S&P/ASX 300 index, reflecting its strengthened market presence.
EZZ's Strategic US Partnership
Enhancing its international footprint, EZZ Life Science (ASX:EZZ) has aligned with a US manufacturing partner, GLSP Inc, to produce its supplements for the North American market. This collaboration promises greater operational efficiency and compliance with stringent quality standards. Previously centering on the Chinese market, EZZ is now eyeing the lucrative $100 billion US supplement market, diversifying its reach and potential customer base. With FDA approval for several products, EZZ is poised to expand its offering significantly.
